References
- D’Agostino, R., Chase, W., and Belanger, A. (1988), “The Appropriateness of Some Common Procedures for Testing the Equality of Two Independent Binomial Populations,” The American Statistician, 42, 198–202.
- Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., Hogan, M. C., Dillon, J. J., Hickson, L. J., Li, X., and Cattran, D. C. (2010), “Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study,” Clinical Journal of the American Society of Nephrology, 5, 2188–2198.
- Galbraith, S., and Marschner, I. C. (2003), “Interim Analysis of Continuous Long-Term Endpoints in Clinical Trials With Longitudinal Outcomes,” Statistics in Medicine, 22, 1787–1805.
- Kittelson, J. M., Sharples, K., and Emerson, S. S. (2005), “Group Sequential Clinical Trials for Longitudinal Data With Analyses Using Summary Statistics,” Statistics in Medicine, 24, 2457–2475.
- Laird, N. M., and Ware, J. H. (1982), “Random-Effects Models for Longitudinal Data,” Biometrics, 38, 963–974.
- Lee, J. W., and Demets, D. L. (1991), “Sequential Comparison of Changes With Repeated Measurements Data,” Journal of the American Statistical Association, 86, 757–762.
- Marschner, I. C., and Becker, S. L. (2001), “Interim Monitoring of Clinical Trials Based on Long-Term Binary Endpoints,” Statistics in Medicine, 20, 177–192.
- Shih, W. J., and Quan, H. (1999), “Planning and Analysis of Repeated Measures at Key Time-Points in Clinical Trials Sponsored by Pharmaceutical Companies,” Statistics in Medicine, 18, 961–973.